Tag: Prescription Drugs

Displaying 1 - 20 of 153 results.

Pharmaceutical companies Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. have agreed to divest Ranbaxy’s interests in generic minocycline tablets  in order to settle Federal Trade Commission charges that Sun’s $4 billion proposed acquisition of Ranbaxy would likely be...
Global pharmaceutical company Novartis AG has agreed to divest Habitrol, its nicotine replacement therapy patch, to settle FTC charges that its consumer health care products joint venture with GlaxoSmithKline (GSK) would likely be anticompetitive. GSK currently sells its own nicotine replacement...
In a recently published article, we discuss our finding that generic drug companies successfully use low-pricing strategies to discourage entry by new competitors in certain circumstances.
Brief of the Federal Trade Commission as Amicus Curiae before the United States District Court for the Eastern District of Pennsylvania, addressing whether a branded company's commitment not to launch an authorized generic in competition with a generic company can constitute a...
Increased competition from the Internet has raised a concern of product quality for online prescription drugs. The Food and Drug Administration (FDA) prohibits the importation of unapproved drugs into the US and the National Association of Boards of Pharmacy (NABP) emphasizes their...
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. will sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle Federal Trade Commission charges that Akorn’s proposed $640 million acquisition of Hi-Tech...
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines. You can view a live webcast of the workshop on the FTC’s website, or follow live tweets...
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.

Pages